<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02165124</url>
  </required_header>
  <id_info>
    <org_study_id>NA_00093563</org_study_id>
    <nct_id>NCT02165124</nct_id>
  </id_info>
  <brief_title>Bariatric Embolization of Arteries for the Treatment of Obesity</brief_title>
  <acronym>BEAT Obesity</acronym>
  <official_title>Bariatric Embolization of Arteries for the Treatment of Obesity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Icahn School of Medicine at Mount Sinai</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is evaluate the safety and effectiveness of bariatric embolization
      as a minimally-invasive image-guided procedure for morbid obesity. In this procedure,
      specific blood vessels to the stomach are blocked in order to suppress some of the body's
      signals for feeling hungry, leading to weight loss.

      Morbid obesity is currently treated with diet and exercise, medications, and surgery. This
      study is designed to help treat obesity using a minimally invasive, non-surgical,
      angiographic (through the blood vessel) approach. This procedure is similar to a common
      procedure used to treat bleeding within the stomach. This version of the procedure has been
      named &quot;bariatric embolization&quot;.

      Although there are over 40 hormones that limit food intake, there is only one hormone,
      ghrelin that has been shown to stimulate (prompt) food intake. In obese patients, eating
      fails to suppress ghrelin levels, which is believed to prevent feeling full after a meal and
      to lead to overeating. Due to the strong hunger craving effects of ghrelin, this hormone has
      been a target for the treatment of obesity and weight loss. More recently, ghrelin has been
      shown to have a significant role in the long-term effect of weight loss in bariatric
      (obesity) surgery where ghrelin levels are shown to be much lower when compared to untreated
      patients.

      Recent data collected in animals in has shown that blocking blood vessels to a particular
      portion of the stomach (bariatric embolization) can temporarily decrease levels of the
      appetite inducing hormone ghrelin, and decrease short-term weight gain. In a study of 5
      people, there was a decrease in ghrelin levels and weight loss in the first month after the
      procedure, but there is no information about the effects of the procedure over longer periods
      of time.

      The investigator hopes to learn if bariatric embolization results in safe and effective
      weight loss in people who are morbidly obese.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Actual">March 2018</completion_date>
  <primary_completion_date type="Actual">December 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Weight Change</measure>
    <time_frame>12 Months</time_frame>
    <description>This will be assessed by Percentage of excess weight loss (EWL). Percentage of excess weight loss is calculated by measuring the participants excess weight at baseline and then calculating the percentage of excess weight that was lost 12 months after surgery (for example if a participant has 100 pounds of excess weight prior to surgery and loses 30 pounds, their excess weight loss would be 30%).</description>
  </primary_outcome>
  <other_outcome>
    <measure>Blood Pressure</measure>
    <time_frame>12 Months</time_frame>
    <description>Unit of Measure: mmHg</description>
  </other_outcome>
  <other_outcome>
    <measure>Lipid Panel</measure>
    <time_frame>12 Months</time_frame>
    <description>Unit of Measure: mg/dL, Total cholesterol, High-density lipoprotein cholesterol (HDL-C) — often called &quot;good cholesterol&quot; , Low-density lipoprotein cholesterol (LDL-C) — often called &quot;bad cholesterol&quot; and Triglycerides</description>
  </other_outcome>
  <other_outcome>
    <measure>Ghrelin Levels</measure>
    <time_frame>12 Months</time_frame>
    <description>Unit of Measure: pg/mL, Ghrelin on the other hand is a fast-acting hormone, seemingly playing a role in meal initiation.</description>
  </other_outcome>
  <other_outcome>
    <measure>Serum Obesity Hormone(Leptin)</measure>
    <time_frame>12 Months</time_frame>
    <description>This will be assessed by Leptin concentration
Unit of Measure: pg/mL, Leptin is a mediator of long-term regulation of energy balance, suppressing food intake and thereby inducing weight loss.</description>
  </other_outcome>
  <other_outcome>
    <measure>Eating and Hunger/Satiety Assessments</measure>
    <time_frame>12 Months</time_frame>
    <description>Unit of Measure: N/A Utilizing 3-Factor Eating Questionnaire Scores</description>
  </other_outcome>
  <other_outcome>
    <measure>Quality of Life Parameters Survey</measure>
    <time_frame>12 Months</time_frame>
    <description>Unit of Measure: N/A Utilizing Short Form Health Survey (SF)-36 and Impact of Weight on Quality of Life (IWQOL)-Lite</description>
  </other_outcome>
  <other_outcome>
    <measure>Food Intake</measure>
    <time_frame>12 Months</time_frame>
    <description>Documented via journal entries</description>
  </other_outcome>
  <other_outcome>
    <measure>Results From Endoscopy</measure>
    <time_frame>12 Months</time_frame>
    <description>Photos and clinical reports analyzed</description>
  </other_outcome>
  <other_outcome>
    <measure>Gastric Motility/Emptying</measure>
    <time_frame>12 Months</time_frame>
    <description>Unit of Measure: (t 1/2) in minutes, A gastric emptying scan (GES) is a nuclear medicine exam that uses a radioactive material that you will eat in a meal. You will eat this meal in the Radiology department before your scan. The radioactive material allows doctors to see how your stomach empties.
This scan is used to help diagnose conditions called motility disorders. These are conditions that change the way the stomach contracts and moves food into your intestines. A GES is a form of radiology, because radiation is used to take pictures of your body.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Morbid Obesity</condition>
  <arm_group>
    <arm_group_label>Intervention/Bariatric Embolization</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Artificial Embolization Device</intervention_name>
    <description>Embosphere Microspheres</description>
    <arm_group_label>Intervention/Bariatric Embolization</arm_group_label>
    <other_name>Device Product Codes: 85 NAJ</other_name>
    <other_name>Classification Name: Artificial Embolization Device</other_name>
    <other_name>Regulation Numbers: 21 CFR 882.5950</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Willing, able and mentally competent to provide written informed consent.

          2. Body mass index (BMI) between 40-60.

          3. Residence within 25 miles of the enrolling institution

          4. Vascular anatomy (including celiac, hepatic, and gastric arteries) that in the opinion
             of the interventional radiologist amenable to Bariatric Embolization, as assessed on
             3D CT angiography.

          5. Suitable for protocol therapy as determined by the interventional radiology
             Investigator.

          6. Adequate hematological, hepatic and renal function as follows:

             Hematological Neutrophils &gt; 1.5 x 109/L Platelets &gt; 100 x 109/L International
             Normalized Ratio (INR) &lt;1.5

             Hepatic Bilirubin ≤ 2.0 mg/dL Albumin ≥ 2.5 g/L

             Renal Estimated Glomerular Filtration Rate (GFR) &gt; 60ml/min.1.73m2

          7. Aged 18 years or older.

        Exclusion Criteria:

          1. Prior history of gastric pancreatic, hepatic, and/or splenic surgery

          2. Prior radiation to the upper abdomen

          3. Prior embolization to the stomach, spleen or liver

          4. Portal venous hypertension

          5. Prior or current history of peptic ulcer disease

          6. Hiatal Hernia

          7. Significant risk factors for peptic ulcer disease including daily NSAID use and
             smoking.

          8. Active H. Pylori infection

          9. Weight greater than 400 pound

         10. Known aortic pathology such as aneurysm or dissection renal insufficiency as evidenced
             by an estimated glomerular filtration rate of &lt; 60 milliliters per minute

         11. Major comorbidity such as cancer, significant cardiovascular disease, diabetes, or
             peripheral arterial disease.

         12. Complicated arterial anatomic variants including left gastric artery arising from the
             aorta, and/or hepatic arterial supply via a replaced or accessory left hepatic artery
             arising from the left gastric artery.

         13. Pregnancy

         14. Preexisting chronic abdominal pain

         15. Positive stool occult study

         16. Abnormal Endoscopy

         17. Abnormal Nuclear Gastric Motility examination

         18. American Society of Anaesthesiologists (ASA) Class 4 or 5 (very high risk surgical
             candidates: class 4= incapacitating disease that is a constant threat to life) at the
             time of screening for enrollment into the study will be excluded from participation.
             This exclusion criterion exists because of the possibility that surgical intervention
             will be needed if the study intervention subsequently leads to severe adverse effects.

         19. History of Inflammatory Bowel Disease

         20. Autoimmune disease

         21. Cirrhosis

         22. Known history of allergy to iodinated contrast media
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clifford R Weiss, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Aravind Arepally, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Piedmont Healthcare</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dara L Kraitchman, V.M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lawrence Cheskin, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Aaron Fischman, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Icahn School of Medicine at Mount Sinai - aaron.fischman@mountsinai.org ; 212-241-7409</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ellen Weiss, B.S, M.A, M.S</last_name>
    <role>Study Chair</role>
    <affiliation>Icahn School of Medicine at Mount Sinai - ellen.weiss@mountsinai.org ; 212-241-2317</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Johns Hopkins Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>June 11, 2014</study_first_submitted>
  <study_first_submitted_qc>June 13, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 17, 2014</study_first_posted>
  <results_first_submitted>September 24, 2018</results_first_submitted>
  <results_first_submitted_qc>November 1, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">November 5, 2018</results_first_posted>
  <last_update_submitted>November 1, 2018</last_update_submitted>
  <last_update_submitted_qc>November 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Obesity</keyword>
  <keyword>Morbid Obesity</keyword>
  <keyword>Bariatric Surgery</keyword>
  <keyword>Embolization</keyword>
  <keyword>Minimally Invasive</keyword>
  <keyword>Weight Loss</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Obesity, Morbid</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 17, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/24/NCT02165124/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Intervention/Bariatric Embolization</title>
          <description>Artificial Embolization Device: Embosphere Microspheres</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Intervention/Bariatric Embolization</title>
          <description>Artificial Embolization Device: Embosphere Microspheres</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44.5" spread="10.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent Weight Change</title>
        <description>This will be assessed by Percentage of excess weight loss (EWL). Percentage of excess weight loss is calculated by measuring the participants excess weight at baseline and then calculating the percentage of excess weight that was lost 12 months after surgery (for example if a participant has 100 pounds of excess weight prior to surgery and loses 30 pounds, their excess weight loss would be 30%).</description>
        <time_frame>12 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intervention/Bariatric Embolization</title>
            <description>Artificial Embolization Device: Embosphere Microspheres</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Weight Change</title>
          <description>This will be assessed by Percentage of excess weight loss (EWL). Percentage of excess weight loss is calculated by measuring the participants excess weight at baseline and then calculating the percentage of excess weight that was lost 12 months after surgery (for example if a participant has 100 pounds of excess weight prior to surgery and loses 30 pounds, their excess weight loss would be 30%).</description>
          <units>percentage of excess weight loss</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.5" spread="10.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Blood Pressure</title>
        <description>Unit of Measure: mmHg</description>
        <time_frame>12 Months</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Lipid Panel</title>
        <description>Unit of Measure: mg/dL, Total cholesterol, High-density lipoprotein cholesterol (HDL-C) — often called &quot;good cholesterol&quot; , Low-density lipoprotein cholesterol (LDL-C) — often called &quot;bad cholesterol&quot; and Triglycerides</description>
        <time_frame>12 Months</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Ghrelin Levels</title>
        <description>Unit of Measure: pg/mL, Ghrelin on the other hand is a fast-acting hormone, seemingly playing a role in meal initiation.</description>
        <time_frame>12 Months</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Serum Obesity Hormone(Leptin)</title>
        <description>This will be assessed by Leptin concentration
Unit of Measure: pg/mL, Leptin is a mediator of long-term regulation of energy balance, suppressing food intake and thereby inducing weight loss.</description>
        <time_frame>12 Months</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Eating and Hunger/Satiety Assessments</title>
        <description>Unit of Measure: N/A Utilizing 3-Factor Eating Questionnaire Scores</description>
        <time_frame>12 Months</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Quality of Life Parameters Survey</title>
        <description>Unit of Measure: N/A Utilizing Short Form Health Survey (SF)-36 and Impact of Weight on Quality of Life (IWQOL)-Lite</description>
        <time_frame>12 Months</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Food Intake</title>
        <description>Documented via journal entries</description>
        <time_frame>12 Months</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Results From Endoscopy</title>
        <description>Photos and clinical reports analyzed</description>
        <time_frame>12 Months</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Gastric Motility/Emptying</title>
        <description>Unit of Measure: (t 1/2) in minutes, A gastric emptying scan (GES) is a nuclear medicine exam that uses a radioactive material that you will eat in a meal. You will eat this meal in the Radiology department before your scan. The radioactive material allows doctors to see how your stomach empties.
This scan is used to help diagnose conditions called motility disorders. These are conditions that change the way the stomach contracts and moves food into your intestines. A GES is a form of radiology, because radiation is used to take pictures of your body.</description>
        <time_frame>12 Months</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>30 Days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Intervention/Bariatric Embolization</title>
          <description>Artificial Embolization Device: Embosphere Microspheres</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>asymptomatic gastric ulcers discovered on endoscopy</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Clifford Weiss</name_or_title>
      <organization>Johns Hopkins Univesity</organization>
      <phone>4106141046</phone>
      <email>cweiss@jhmi.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

